Litigation Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Docket		Date Filed	2017-05-18
Court	Court of Appeals for the Federal Circuit	Date Terminated	2019-03-28
Cause		Assigned To
Jury Demand		Referred To
Patents	8,536,130
Link to Docket	External link to docket

Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-18				External link to document

Litigation summary and analysis for: Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Last updated: October 29, 2026

Executive summary: The Federal Circuit affirmed the invalidity of Grunenthal GmbH's asserted tapentadol extended-release patent claims in Grunenthal GmbH v. Alkem Laboratories Ltd., No. 17-2050, 919 F.3d 1333 (Fed. Cir. 2019). The court held that the asserted claims of U.S. Patent No. 8,337,888 were obvious over the cited prior art. The decision removed the principal patent obstacle raised against Alkem's ANDA for a generic version of Nucynta ER, subject to FDA approval and any other unexpired regulatory or patent barriers.

Grunenthal GmbH v. Alkem Laboratories Limited, No. 17-2050: Litigation Summary and Patent Analysis

What was Grunenthal GmbH v. Alkem Laboratories about?

The case concerned Alkem's abbreviated new drug application for an extended-release tapentadol product. Grunenthal, the developer and patent owner associated with Nucynta ER, sued Alkem under the Hatch-Waxman Act after receiving a Paragraph IV certification challenging the listed patent.

The Federal Circuit case addressed U.S. Patent No. 8,337,888, which covered controlled-release tapentadol dosage forms and methods of treating pain using those dosage forms. The central question was whether the asserted claims were nonobvious in view of the prior art.

Item	Detail
Federal Circuit docket	No. 17-2050
Case	Grunenthal GmbH v. Alkem Laboratories Ltd.
Decision	919 F.3d 1333
Court	U.S. Court of Appeals for the Federal Circuit
Decision year	2019
Plaintiff-appellant	Grunenthal GmbH
Defendant-appellee	Alkem Laboratories Limited
Product	Extended-release tapentadol
Brand reference	Nucynta ER
Principal patent	U.S. Patent No. 8,337,888
Legal issue	Obviousness under 35 U.S.C. § 103
Result	District court judgment of invalidity affirmed

What patent protected Nucynta ER in the Alkem litigation?

The principal patent was U.S. Patent No. 8,337,888. The patent claimed pharmaceutical compositions and treatment methods involving controlled-release tapentadol.

Tapentadol is a centrally acting opioid analgesic. Nucynta ER uses an extended-release formulation intended to provide prolonged analgesia and reduce dosing frequency compared with immediate-release tapentadol.

The asserted patent claims focused on the combination of:

• Tapentadol or a pharmaceutically acceptable salt;
• A controlled-release dosage form;
• Extended release over a specified period;
• Treatment of pain in a patient; and
• A dosage regimen intended to provide therapeutic effect for approximately 12 hours or longer.

The case did not concern whether tapentadol itself was a new chemical entity. It concerned the patentability of the extended-release dosage form and the related treatment method.

What did the Federal Circuit decide in Grunenthal v. Alkem?

The Federal Circuit affirmed the district court's determination that the asserted claims were obvious.

The appellate court applied the standard four-part obviousness framework:

1. The scope and content of the prior art;
2. Differences between the prior art and the asserted claims;
3. The level of ordinary skill in the art; and
4. Objective indicia of nonobviousness, such as commercial success or unexpected results.

The court agreed that the prior art disclosed the relevant technical components of the claimed tapentadol extended-release product. The existence of formulation work and optimization did not, on the facts of the case, convert the claimed invention into a patentable advance.

The Federal Circuit also rejected Grunenthal's arguments concerning motivation to combine and reasonable expectation of success. The court treated the formulation problem as one that a skilled pharmaceutical formulator would have been motivated to address using known controlled-release technologies.

Why was the obviousness finding significant?

The decision reinforced several principles relevant to pharmaceutical formulation patents:

• A controlled-release formulation is not automatically nonobvious because it requires experimentation.
• Routine optimization of release characteristics can support an obviousness finding where the prior art provides a reason to pursue the claimed result.
• The existence of multiple possible formulation approaches does not necessarily defeat obviousness.
• Commercial success has limited force where the claimed commercial product is closely tied to advantages already disclosed or expected from the prior art.
• Unexpected results must be commensurate in scope with the asserted claims.

The decision did not establish that all extended-release tapentadol patents were invalid. It addressed the particular claims and evidence presented for the '888 patent.

What was the procedural history of the case?

Grunenthal sued Alkem after Alkem filed an ANDA containing a Paragraph IV certification against the relevant patent. The action was a patent infringement case under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA challenging an Orange Book-listed patent as an act of infringement for purposes of resolving patent rights before commercial launch.

The district court held that the asserted claims were invalid for obviousness. Grunenthal appealed to the Federal Circuit.

The Federal Circuit affirmed the judgment. The appellate decision therefore left the patent claims unenforceable against Alkem on the grounds that they were invalid.

Procedural event	Outcome
ANDA filing by Alkem	Triggered Hatch-Waxman patent litigation
District court litigation	Asserted claims held obvious
Grunenthal appeal	Filed in Federal Circuit docket No. 17-2050
Federal Circuit decision	District court judgment affirmed
Post-appeal effect	No enforceable '888 patent claims remained against Alkem

What was the Paragraph IV challenge?

A Paragraph IV certification asserts that a patent listed for the reference drug is invalid, unenforceable, or will not be infringed by the ANDA product.

Alkem's Paragraph IV position placed the '888 patent directly in dispute. Grunenthal's lawsuit delayed FDA approval of the ANDA through the statutory 30-month stay, unless the litigation ended earlier or another statutory event applied.

The Federal Circuit's affirmance eliminated the invalidated patent as a basis for continued exclusion of Alkem. The decision did not itself grant FDA approval. FDA approval remained dependent on the ANDA's regulatory status, including bioequivalence, labeling, manufacturing, and exclusivity requirements.

What was the Orange Book status of the patent?

The litigation arose from an Orange Book-listed patent for the reference product's extended-release tapentadol product. The Orange Book listing gave Grunenthal a mechanism to challenge Alkem's ANDA before commercial marketing.

The practical impact of a patent invalidity judgment is product-specific:

• The invalidated patent can no longer support an injunction against the accused ANDA product.
• Other listed patents may continue to delay approval or launch.
• Regulatory exclusivity is separate from patent protection.
• A generic applicant can remain subject to other patents, labeling restrictions, or FDA review requirements.

The Federal Circuit decision did not invalidate every Nucynta or tapentadol patent. It invalidated the asserted claims at issue in the appeal.

When did the relevant patent lose effective protection?

The '888 patent lost practical litigation value against Alkem when the Federal Circuit affirmed the judgment that the asserted claims were invalid. That event occurred before the patent's ordinary statutory expiration and was more important to the Alkem case than the nominal expiration date.

Patent term and patent validity are separate:

Protection type	Effect of the Federal Circuit decision
Patent validity	Asserted claims held invalid
Patent expiration	Became commercially less important for the claims at issue
FDA exclusivity	Not decided by the Federal Circuit
Other Nucynta patents	Not automatically affected
Alkem ANDA approval	Not automatically granted by the court

A patent that remains within its term but has been held invalid cannot ordinarily support an injunction based on the invalidated claims. The decision therefore created an earlier generic-entry opportunity than expiration alone would have provided.

Did the case involve formulation patents or method-of-use patents?

Yes. The '888 patent involved both formulation-related limitations and therapeutic-use limitations.

The formulation component addressed a controlled-release dosage form containing tapentadol. The method-of-use component addressed administering the dosage form to treat pain over an extended therapeutic interval.

This combination can complicate litigation because the patentee may argue that the formulation and treatment regimen produce a clinically distinct result. The Federal Circuit nevertheless evaluated the claims as a combination of known technical elements and found the claimed arrangement obvious.

For future formulation cases, the decision is relevant to:

• Controlled-release opioid formulations;
• Twelve-hour dosing regimens;
• Dissolution and release profiles;
• Formulation optimization;
• Method claims tied to dosage duration; and
• Evidence of unexpected pharmacokinetic or clinical performance.

How strong was Grunenthal's patent estate after the decision?

The decision materially weakened Grunenthal's protection for extended-release tapentadol against Alkem. The strength of the broader estate depended on other listed patents, unasserted claims, and any later-issued patents.

The ruling should not be read as a finding that all tapentadol intellectual property was invalid. Its direct holding was narrower:

• The asserted claims of the '888 patent were obvious.
• The district court's judgment was affirmed.
• The ruling applied to the patent claims and evidence before the court.
• Other patents required separate validity and infringement analysis.

For a generic entrant, the decision reduced one major litigation risk. For the brand company, it increased the importance of any remaining formulation, manufacturing, polymorph, dosage, labeling, or method-of-use patents.

Did the case involve biosimilar risk?

No. Tapentadol is a small-molecule drug, and Alkem's product was pursued through the ANDA pathway rather than the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant competitive risks were:

• Generic substitution;
• ANDA approval;
• Paragraph IV litigation;
• 180-day generic exclusivity, if applicable;
• Remaining Orange Book patents; and
• Commercial launch strategy.

Biosimilar concepts such as interchangeability, reference biologics, and patent dance procedures were not relevant to this case.

What was the commercial impact of the ruling?

The ruling increased the possibility of generic competition for extended-release tapentadol. It removed the '888 patent as an enforceable barrier against Alkem, but it did not establish the actual launch date or market share of an Alkem product.

The decision's commercial implications were:

1. A reduced patent-based delay risk for Alkem.
2. Greater pressure on Nucynta ER pricing if a generic entered.
3. Potential erosion of branded extended-release tapentadol revenue.
4. Increased importance of remaining patents and regulatory exclusivity.
5. A stronger basis for generic manufacturers to evaluate similar formulation strategies.

The reported appellate decision does not provide a quantified Nucynta revenue figure, settlement payment, or market-share forecast. Those figures should not be inferred from the judgment.

Was there a settlement agreement?

The Federal Circuit opinion reports an adjudicated validity dispute and an affirmance of the district court's judgment. It does not identify a settlement agreement that would independently control Alkem's launch date.

A Hatch-Waxman settlement, if one existed outside the appellate opinion, would need to be evaluated separately for:

• Agreed entry date;
• Authorized-generic terms;
• Payment or other consideration;
• No-challenge provisions;
• Remaining patent claims; and
• FTC or DOJ reporting.

The reported appellate outcome is an invalidity judgment, not a settlement-based market-entry ruling.

Which companies were challenging or exposed to the Nucynta ER patent estate?

Alkem was the defendant in this appeal. Other generic applicants could have separate ANDAs and separate litigation positions. The Federal Circuit decision did not automatically determine the rights of every other applicant.

The competitive field included:

• Grunenthal as the patent holder and innovator-side party;
• Alkem as the ANDA applicant;
• Other potential generic manufacturers evaluating tapentadol ER;
• FDA as the regulator responsible for ANDA review; and
• Commercial partners or licensees involved in manufacturing and distribution.

A ruling that a patent is obvious can have collateral commercial value for other ANDA applicants, but each applicant still faces product-specific patent and regulatory issues.

What manufacturing and intellectual-property barriers remained?

The judgment did not remove non-patent barriers. A generic extended-release tapentadol product still requires:

• Demonstration of bioequivalence;
• Compliance with controlled-substance requirements;
• Manufacturing approval and inspection;
• Commercial-scale release-control consistency;
• Appropriate labeling;
• Sourcing of active pharmaceutical ingredient;
• Abuse-deterrence and safety assessment where applicable; and
• Resolution of any remaining listed patents.

The invalidity ruling addressed the '888 patent. It did not decide whether Alkem's formulation infringed other patents or whether the product met all FDA requirements.

What are the main legal precedents from the decision?

The decision is most relevant for pharmaceutical obviousness disputes involving formulation patents. Its practical lessons are:

• Patent claims must be assessed as a whole, but known formulation elements can still support obviousness when combined for their expected functions.
• A skilled artisan's ability to optimize a formulation does not necessarily create patentable subject matter.
• Evidence of commercial success must be connected to the claimed invention.
• Unexpected results must be shown across the claim scope.
• An appellate court will defer to factual findings unless they are clearly erroneous, while reviewing the ultimate obviousness determination without deference.

Key Takeaways

• Grunenthal GmbH v. Alkem Laboratories Ltd., No. 17-2050, involved an ANDA challenge to the Nucynta ER patent estate.
• The Federal Circuit affirmed the invalidity of the asserted claims of U.S. Patent No. 8,337,888.
• The claims were held obvious under 35 U.S.C. § 103.
• The ruling removed the '888 patent as a litigation barrier against Alkem.
• The case concerned a small-molecule generic, not a biosimilar.
• The decision did not invalidate every tapentadol patent or guarantee FDA approval.
• Remaining patents, regulatory exclusivity, controlled-substance requirements, manufacturing, and bioequivalence remained relevant.
• The opinion does not establish a settlement, launch date, revenue amount, or market-share outcome.

FAQs About Grunenthal v. Alkem

What drug was at issue in Grunenthal v. Alkem?

The case involved extended-release tapentadol, marketed by Grunenthal and its commercial partners as Nucynta ER.

What patent number was invalidated in the case?

The principal patent was U.S. Patent No. 8,337,888, directed to controlled-release tapentadol compositions and treatment methods.

Did Alkem win the Federal Circuit appeal?

Yes. The Federal Circuit affirmed the district court's judgment that the asserted claims were obvious.

Did the ruling authorize immediate generic launch?

No. The ruling removed the asserted patent barrier but did not order FDA approval or establish an immediate commercial launch date.

Is Grunenthal v. Alkem relevant to extended-release formulation patents?

Yes. The decision is relevant to obviousness analysis for controlled-release dosage forms, formulation optimization, dosing-interval claims, and method claims tied to extended therapeutic duration.

References

1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
2. Grunenthal GmbH v. Alkem Laboratories Ltd., 919 F.3d 1333 (Fed. Cir. 2019).
3. Hatch-Waxman Amendments, Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
4. U.S. Patent No. 8,337,888, “Pharmaceutical compositions comprising tapentadol,” issued Dec. 25, 2012.
5. U.S. Food and Drug Administration. (2019). Approved drug products with therapeutic equivalence evaluations [Orange Book].